.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Argus Health
Queensland Health
Fuji
Johnson and Johnson
Citi
US Army
Merck
Deloitte

Generated: December 15, 2017

DrugPatentWatch Database Preview

Patents Expiring in June 2022

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer HlthcareSTIVARGAregorafenibTABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeJUVISYNCsimvastatin; sitagliptin phosphateTABLET;ORAL202343-003Oct 7, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
Merck Sharp DohmeJUVISYNCsimvastatin; sitagliptin phosphateTABLET;ORAL202343-004Sep 18, 2012DISCNYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
Merck Sharp DohmeJUVISYNCsimvastatin; sitagliptin phosphateTABLET;ORAL202343-001Oct 7, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Baxter
AstraZeneca
US Department of Justice
Fuji
McKesson
US Army
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot